Robotic lateral pelvic lymph node dissection after chemoradiation for rectal cancer: a Western perspective.
Lateral pelvic lymph node
neoadjuvant chemoradiotherapy
rectal cancer
robotic
Journal
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
ISSN: 1463-1318
Titre abrégé: Colorectal Dis
Pays: England
ID NLM: 100883611
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
revised:
06
08
2020
received:
13
06
2020
accepted:
25
08
2020
pubmed:
7
9
2020
medline:
19
8
2021
entrez:
6
9
2020
Statut:
ppublish
Résumé
There are limited outcome data for lateral pelvic lymph node dissection (LPLND) following neoadjuvant chemoradiotherapy (nCRT), particularly in the West. Our aim was to evaluate the short-term perioperative and oncological outcomes of robotic LPLND at a single cancer centre. A retrospective analysis of a prospective database of consecutive patients undergoing robotic LPLND for rectal cancer between November 2012 and February 2020 was performed. The main outcomes were short-term perioperative and oncological outcomes. Major morbidity was defined as Clavien-Dindo grade 3 or above. Forty patients underwent robotic LPLND during the study period. The mean age was 54 years (SD ± 15 years) and 13 (31.0%) were female. The median body mass index was 28.6 kg/m Robotic LPLND for rectal cancer can be performed in Western patients to completely resect extra-mesorectal LPLNs and is associated with acceptable perioperative morbidity.
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2049-2056Subventions
Organisme : NCI NIH HHS
ID : T32 CA009599
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA016672
Pays : United States
Informations de copyright
© 2020 The Association of Coloproctology of Great Britain and Ireland.
Références
Hashiguchi Y, Muro K, Saito Y et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol 2019; 25: 1-42.
Georgiou P, Tan E, Gouvas N et al. Extended lymphadenectomy versus conventional surgery for rectal cancer: a meta-analysis. Lancet Oncol 2009; 10: 1053-62.
Kusters M, Beets GL, van de Velde CJ et al. A comparison between the treatment of low rectal cancer in Japan and the Netherlands, focusing on the patterns of local recurrence. Ann Surg 2009; 249: 229-35.
Yano H, Moran BJ. The incidence of lateral pelvic side-wall nodal involvement in low rectal cancer may be similar in Japan and the West. Br J Surg 2008; 95: 33-49.
Sammour T, Chang GJ. Lateral pelvic lymph node dissection and radiation treatment for rectal cancer: mutually exclusive or mutually beneficial? Ann Gastroenterol Surg 2018; 2: 348-50.
Sammour T, Chang GJ. Lateral node dissection in low rectal cancer: time for a global approach? Ann Surg 2017; 266: 208-9.
Malakorn S, Chang GJ. Treatment of rectal cancer in the East and West: Should it be different? Surgery 2017; 162: 315-6.
Ogura A, Konishi T, Cunningham C et al. Neoadjuvant (Chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: results of the multicenter lateral node study of patients with low cT3/4 rectal cancer. J Clin Oncol 2019; 37: 33-43.
Malakorn S, Yang Y, Bednarski BK et al. Who should get lateral pelvic lymph node dissection after neoadjuvant chemoradiation? Dis Colon Rectum 2019; 62: 1158-66.
Kim HJ, Choi GS, Park JS et al. Selective lateral pelvic lymph node dissection: a comparative study of the robotic versus laparoscopic approach. Surg Endosc 2018; 32: 2466-73.
Malakorn S, Ouchi A, Sammour T, Bednarski BK, Chang GJ. Robotic lateral pelvic lymph node dissection after neoadjuvant chemoradiation: view from the west. Dis Colon Rectum 2018; 61: 1119-20.
Kim MJ, Kim TH, Kim DY et al. Can chemoradiation allow for omission of lateral pelvic node dissection for locally advanced rectal cancer? J Surg Oncol 2015; 111: 459-64.
Fujita S, Mizusawa J, Kanemitsu Y et al. Mesorectal excision with or without lateral lymph node dissection for clinical stage II/III lower rectal cancer (JCOG0212): a multicenter, randomized controlled, noninferiority trial. Ann Surg 2017; 266: 201-7.
Kusters M, Slater A, Muirhead R et al. What to do with lateral nodal disease in low locally advanced rectal cancer? A call for further reflection and research. Dis Colon Rectum 2017; 60: 577-85.
Akiyoshi T, Ueno M, Matsueda K et al. Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging. Ann Surg Oncol 2014; 21: 189-96.
Ishihara S, Kawai K, Tanaka T et al. Oncological outcomes of lateral pelvic lymph node metastasis in rectal cancer treated with preoperative chemoradiotherapy. Dis Colon Rectum 2017; 60: 469-76.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-4.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-13.
Park IJ, You YN, Skibber JM et al. Oncologic and functional hazards of obesity among patients with locally advanced rectal cancer following neoadjuvant chemoradiation therapy. Am J Clin Oncol 2017; 40: 277-82.
Fujita S, Akasu T, Mizusawa J et al. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial. Lancet Oncol 2012; 13: 616-21.
Ogura A, Akiyoshi T, Nagasaki T et al. Feasibility of laparoscopic total mesorectal excision with extended lateral pelvic lymph node dissection for advanced lower rectal cancer after preoperative chemoradiotherapy. World J Surg 2017; 41: 868-75.
Ito M, Kobayashi A, Fujita S et al. Urinary dysfunction after rectal cancer surgery: Results from a randomized trial comparing mesorectal excision with and without lateral lymph node dissection for clinical stage II or III lower rectal cancer (Japan Clinical Oncology Group Study, JCOG0212). Eur J Surg Oncol 2018; 44: 463-8.
Bednarski BK, Nickerson TP, You YN et al. Randomized clinical trial of accelerated enhanced recovery after minimally invasive colorectal cancer surgery (RecoverMI trial). Br J Surg 2019; 106: 1311-8.
Nonaka T, Fukuda A, Maekawa K et al. Clinical and oncological outcomes of laparoscopic lateral pelvic lymph node dissection in advanced lower rectal cancer: single-institution experience. Anticancer Res 2017; 37: 5095-100.
Nagayoshi K, Ueki T, Manabe T et al. Laparoscopic lateral pelvic lymph node dissection is achievable and offers advantages as a minimally invasive surgery over the open approach. Surg Endosc 2016; 30: 1938-47.
Kagawa H, Kinugasa Y, Shiomi A et al. Robotic-assisted lateral lymph node dissection for lower rectal cancer: short-term outcomes in 50 consecutive patients. Surg Endosc 2015; 29: 995-1000.
Yamaguchi T, Kinugasa Y, Shiomi A, Tomioka H, Kagawa H. Robotic-assisted laparoscopic versus open lateral lymph node dissection for advanced lower rectal cancer. Surg Endosc 2016; 30: 721-8.
Ouyang M, Liao T, Lu Y et al. Laparoscopic versus open surgery in lateral lymph node dissection for advanced rectal cancer: a meta-analysis. Gastroenterol Res Pract 2019; 2019: 7689082.
Kobayashi H, Mochizuki H, Kato T et al. Outcomes of surgery alone for lower rectal cancer with and without pelvic sidewall dissection. Dis Colon Rectum 2009; 52: 567-76.
Akiyoshi T, Toda S, Tominaga T et al. Prognostic impact of residual lateral lymph node metastasis after neoadjuvant (chemo)radiotherapy in patients with advanced low rectal cancer. BJS Open 2019; 3: 822-9.